Nicole E. Scangarella-Oman

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation

Stephanie N. Taylor, David H. Morris, Ann Avery et al. · Clinical Infectious Diseases · 2018 · 158 citations · Full text

Antimicrobial Resistance Trends in Urine <i>Escherichia coli</i> Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management

Keith S. Kaye, Vikas Gupta, Aruni Mulgirigama et al. · Clinical Infectious Diseases · 2021 · 124 citations · Full text

<i>In Vitro</i> Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

Douglas J. Biedenbach, S. Bouchillon, Meredith Hackel et al. · Antimicrobial Agents and Chemotherapy · 2016 · 121 citations · Full text

Bacterial Resistance to Leucyl-tRNA Synthetase Inhibitor GSK2251052 Develops during Treatment of Complicated Urinary Tract Infections

Karen O’Dwyer, Aaron Spivak, Karen Ingraham et al. · Antimicrobial Agents and Chemotherapy · 2014 · 97 citations · Full text

Microbial Pathogens, Escherichia Coli Isolates, Antibiotic Resistance +21

Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae

Nicole E. Scangarella-Oman, Mohammad Sharif Hossain, Paula Dixon et al. · Antimicrobial Agents and Chemotherapy · 2018 · 92 citations · Full text